MIRAMAR, Fla., Jan. 24, 2020 (GLOBE NEWSWIRE) -- G
Post# of 36537
(Total Views: 337)
Posted On: 01/24/2020 9:01:24 AM
MIRAMAR, Fla., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, the company’s Executive Vice President of Research & Development conducted an interview with Mike Elliott of CEO Roadshow, which is available at:
http://ceoroadshow.com/ceoroadshow-interview-...logy-gnbt/
or
https://youtu.be/7w7R4UlkHf4
During the interview, Mr. Purcell spoke about rebuilding Generex in 2019 and transforming the company through acquisitions and restructuring to create a new vision for delivering care for patients with chronic and complex health needs. Mr. Purcell stated, “We are partnering with large primary care and specialty physician practices through patient-focused MSOs that are designed to deliver integrated and collaborative care. In the coming era of outcomes-driven medicine, NuGenerex Health is building end-to-end solutions that improve patient outcomes and enhance practice profitability. We are dedicated to strengthening the doctor/patient relationship by providing cutting edge drugs, medical devices, therapies, and services from the NuGenerex family of subsidiary companies. In 2020, we are poised for growth. We plan to restart our orthopedic/podiatric MSO with new product lines from our subsidiaries Olaregen, Pantheon and MediSource, and the introduction of our software and service offering, DME-IQ. In addition, we plan to launch our integrated care model for diabetes with our physician partners in Arizona. And perhaps most exciting, the ALTuCELL acquisition is expected to close in the near future, and we plan to initiate a clinical development program to treat and potentially cure diabetes with cellular therapy.”
http://ceoroadshow.com/ceoroadshow-interview-...logy-gnbt/
or
https://youtu.be/7w7R4UlkHf4
During the interview, Mr. Purcell spoke about rebuilding Generex in 2019 and transforming the company through acquisitions and restructuring to create a new vision for delivering care for patients with chronic and complex health needs. Mr. Purcell stated, “We are partnering with large primary care and specialty physician practices through patient-focused MSOs that are designed to deliver integrated and collaborative care. In the coming era of outcomes-driven medicine, NuGenerex Health is building end-to-end solutions that improve patient outcomes and enhance practice profitability. We are dedicated to strengthening the doctor/patient relationship by providing cutting edge drugs, medical devices, therapies, and services from the NuGenerex family of subsidiary companies. In 2020, we are poised for growth. We plan to restart our orthopedic/podiatric MSO with new product lines from our subsidiaries Olaregen, Pantheon and MediSource, and the introduction of our software and service offering, DME-IQ. In addition, we plan to launch our integrated care model for diabetes with our physician partners in Arizona. And perhaps most exciting, the ALTuCELL acquisition is expected to close in the near future, and we plan to initiate a clinical development program to treat and potentially cure diabetes with cellular therapy.”
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼